CYP 6.38% 25.0¢ cynata therapeutics limited

Ann: Cynata GvHD Trial Meets all Safety & Efficacy Endpoints, page-38

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 35,472 Posts.
    lightbulb Created with Sketch. 2863
    You are so off the tolley re: Tech
    We have already proven Cymerus is superior to MSB BM cells.

    In GvHD (by a country mile so far) but also Asthma where MSB cells were inferior. at Monash where MSB have been for Years!

    MSB had it's day, the new dawn is not non-scalable/ individual GEN 1 extraction.

    History is this space. (not to mention non reimbursement advice recently due to costs)
 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.